News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,618 Results
Type
Article (52859)
Company Profile (209)
Press Release (624550)
Multimedia
Podcasts (62)
Webinars (10)
Section
Business (186114)
Career Advice (2728)
Deals (33442)
Drug Delivery (102)
Drug Development (85272)
Employer Resources (156)
FDA (17069)
Job Trends (14594)
News (330114)
Policy (33006)
Tag
Academia (2816)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (90)
Alliances (49901)
ALS (98)
Alzheimer's disease (1479)
Antibody-drug conjugate (ADC) (145)
Approvals (17051)
Artificial intelligence (283)
Autoimmune disease (26)
Automation (14)
Bankruptcy (345)
Best Places to Work (11686)
BIOSECURE Act (21)
Biosimilars (111)
Biotechnology (151)
Bladder cancer (81)
Brain cancer (32)
Breast cancer (298)
Cancer (2384)
Cardiovascular disease (193)
Career advice (2292)
Career pathing (31)
CAR-T (165)
Cell therapy (461)
Cervical cancer (21)
Clinical research (69454)
Collaboration (862)
Company closure (1)
Compensation (456)
Complete response letters (26)
COVID-19 (2744)
CRISPR (43)
C-suite (254)
Cystic fibrosis (106)
Data (2247)
Decentralized trials (2)
Denatured (26)
Depression (54)
Diabetes (280)
Diagnostics (6470)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (37)
Drug discovery (128)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (70024)
Editorial (42)
Employer branding (19)
Employer resources (137)
Events (98642)
Executive appointments (757)
FDA (18381)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (790)
Gene editing (110)
Generative AI (29)
Gene therapy (332)
GLP-1 (751)
Government (4653)
Grass and pollen (6)
Guidances (66)
Healthcare (19347)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (132)
Indications (30)
Infectious disease (2898)
Inflammatory bowel disease (148)
Inflation Reduction Act (7)
Influenza (53)
Intellectual property (101)
Interviews (513)
IPO (15783)
IRA (38)
Job creations (3328)
Job search strategy (1901)
Kidney cancer (11)
Labor market (30)
Layoffs (471)
Leadership (23)
Legal (7131)
Liver cancer (77)
Lung cancer (337)
Lymphoma (157)
Machine learning (7)
Management (55)
Manufacturing (302)
MASH (69)
Medical device (13053)
Medtech (13056)
Mergers & acquisitions (18200)
Metabolic disorders (712)
Multiple sclerosis (86)
NASH (20)
Neurodegenerative disease (108)
Neuropsychiatric disorders (30)
Neuroscience (2071)
NextGen: Class of 2025 (6780)
Non-profit (4877)
Now hiring (24)
Obesity (371)
Opinion (264)
Ovarian cancer (78)
Pain (94)
Pancreatic cancer (82)
Parkinson's disease (159)
Partnered (23)
Patents (236)
Patient recruitment (116)
Peanut (48)
People (55309)
Pharmaceutical (50)
Pharmacy benefit managers (17)
Phase I (21938)
Phase II (30570)
Phase III (22640)
Pipeline (1224)
Policy (140)
Postmarket research (2605)
Preclinical (8968)
Press Release (60)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (413)
Real estate (5558)
Recruiting (66)
Regulatory (23460)
Reports (31)
Research institute (2581)
Resumes & cover letters (449)
Rett syndrome (5)
RNA editing (4)
RSV (43)
Schizophrenia (79)
Series A (134)
Series B (91)
Service/supplier (9)
Sickle cell disease (55)
Special edition (18)
Spinal muscular atrophy (160)
Sponsored (31)
Startups (3536)
State (2)
Stomach cancer (16)
Supply chain (65)
Tariffs (32)
The Weekly (35)
Vaccines (748)
Venture capitalists (41)
Weight loss (247)
Women's health (37)
Worklife (18)
Date
Last 7 days (859)
Last 30 days (2455)
Last 365 days (32712)
2025 (10831)
2024 (35246)
2023 (39937)
2022 (50988)
2021 (55403)
2020 (54147)
2019 (47530)
2018 (36106)
2017 (32778)
2016 (31800)
2015 (36879)
2014 (29197)
2013 (24682)
2012 (26183)
2011 (26914)
2010 (25315)
Location
Africa (901)
Alabama (56)
Alaska (6)
Arizona (182)
Arkansas (13)
Asia (41269)
Australia (7208)
California (5990)
Canada (1972)
China (538)
Colorado (267)
Connecticut (283)
Delaware (137)
Europe (92035)
Florida (896)
Georgia (195)
Idaho (60)
Illinois (543)
India (24)
Indiana (300)
Iowa (9)
Japan (159)
Kansas (102)
Kentucky (26)
Louisiana (12)
Maine (67)
Maryland (898)
Massachusetts (4479)
Michigan (217)
Minnesota (354)
Mississippi (2)
Missouri (85)
Montana (31)
Nebraska (24)
Nevada (62)
New Hampshire (66)
New Jersey (1697)
New Mexico (30)
New York (1710)
North Carolina (970)
North Dakota (9)
Northern California (2603)
Ohio (206)
Oklahoma (15)
Oregon (36)
Pennsylvania (1327)
Puerto Rico (13)
Rhode Island (29)
South America (1194)
South Carolina (24)
South Dakota (1)
Southern California (2285)
Tennessee (98)
Texas (908)
United States (22687)
Utah (177)
Virginia (153)
Washington D.C. (64)
Washington State (536)
West Virginia (3)
Wisconsin (49)
677,618 Results for "national institute for clinical excellence nice".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT).
April 4, 2024
·
7 min read
Press Releases
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
April 23, 2025
·
8 min read
NICE Endorses Brainomix AI-Enabled Software in Stroke
The U.K. health assessor the National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix 360 (formerly known as e-Stroke) to help clinical decision making in stroke.
February 7, 2024
·
4 min read
Alzheimer’s disease
Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE
While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”
August 22, 2024
·
2 min read
·
Tristan Manalac
BioCapital
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
CEL-SCI Corporation announced that the British National Institute for Health and Care Excellence has selected Multikine* to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck in the UK.
December 4, 2023
·
5 min read
Press Releases
QbTest Evaluated and Recommended by the National Institute for Health and Care Excellence Diagnostic Assessment Programme
October 23, 2024
·
3 min read
Policy
Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI
The U.K.’s National Institute for Health and Care Excellence has endorsed the use of Eli Lilly’s Zepboundfor weight management in patients with BMI of 35 kg/m2 and above and at least one weight-related comorbidity.
June 5, 2024
·
2 min read
·
Tristan Manalac
Biotech Beach
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending Evkeeza® (evinacumab) to NHS England.
January 4, 2024
·
7 min read
Press Releases
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
January 16, 2025
·
4 min read
Press Releases
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
April 14, 2025
·
5 min read
1 of 67,762
Next
